Results 21 to 30 of about 182,211 (308)
Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites [PDF]
, 1993 Torasemide is a new loop diuretic with a longer half-life and longer action than furosemide in healthy subjects. In order to evaluate the pharmacodynamic effects, single oral doses of furosemide (80 mg) and torasemide (20 mg), which were equipotent in ...
Paumgartner, Gustav +4 more
core +1 more source
Use of piretanide, a new loop diuretic in cirrhosis with ascites. Relationship between the diuretic response and the plasma aldosterone level [PDF]
, 1980 Twenty patients with cirrhosis and ascites but no renal failure were given piretanide, a new loop diuretic, in order to investigate its efficacy and to relate the diuretic response with the pretreatment plasma aldosterone concentration.
Rivera Fillat, Francisca +5 more
core +1 more source
Current management of refractory ascites in patients with cirrhosis
Journal of International Medical Research, 2018 Liver cirrhosis is a health problem worldwide, and ascites is its principal symptom. Refractory ascites is intractable and occurs in 5%–10% of all patients with ascites due to cirrhosis.
Ruihong Zhao +5 more
doaj +1 more source
Frontiers in Immunology, 2019 Background and Aims: Ascites and spontaneous bacterial peritonitis (SBP) are frequent complications of liver cirrhosis. In spite of the clinical impact, knowledge about ascites as an immune cell compartment in liver disease is limited.
Philipp Lutz +17 more
doaj +1 more source
Prognostic value of ascites in patients with liver cirrhosis undergoing cardiac surgery
Journal of Cardiothoracic Surgery, 2023 Introduction Mild or moderate liver cirrhosis increases the risk of complications after cardiac surgery. Ascites is the most common complication associated with liver cirrhosis.
Amila Cizmic +5 more
doaj +1 more source
Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy
Frontiers in Cellular and Infection Microbiology, 2023 Effective antiviral therapy can significantly improve the long-term prognosis of HBV-related decompensated patients, and re-compensation may be achieved in part of the patients. To explore the re-compensation of ascites after HBV suppression and the risk
Mingyu Li +7 more
doaj +1 more source
Journal of Ovarian Research, 2018 Background The death-domain-associated protein (DAXX) was originally identified as a protein that binds to the transmembrane death receptor FAS and enhances both FAS-induced and transforming growth factor-β-dependent apoptosis.
Sheng-Bing Liu +4 more
doaj +1 more source
Contemporary management of pain in cirrhosis: Toward precision therapy for pain
Hepatology, EarlyView., 2022 Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman +4 more
wiley +1 more source
Ascitic fluid analysis for the differentiation of malignancy related and nonmalignant ascites [PDF]
, 1991 The authors tried to differentiate malignancy-related from nonmalignant ascites with a sequence of sensitive followed by specific ascitic-fluid parameters. There were four results of this study. First, of nine parameters investigated in a first series of
Paumgartner, Gustav +4 more
core +1 more source
Hepatology, EarlyView., 2022 Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran +17 more
wiley +1 more source